Country selection
To offer the best possible experience tailored to your national regulatory requirements and the available product portfolio, please choose your country from the following list. This option will be saved throughout the browser session. Thank you!
User experience & privacy
We use cookies to offer you an optimal website experience. This includes cookies necessary for the operation of the website and for the control of our commercial corporate goals, as well as those only used for anonymous statistical purposes, comfort settings or to display personalized content. Please note that based on your settings, not all functions of the website may be available. To find out more, please refer to our Data Privacy Statement.
05/03/2020

Eckert & Ziegler Starts Commercial Production of Lutetium-177

Berlin

Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, S-DAX) has developed a new technology for the production of carrier-free lutetium-177. It is based on the irradiation of ytterbium-176 and the subsequent separation of the resulting lutetium-177 in a radiochemical facility. The process has achieved a particularly high degree of purity. Following the successful validation of the production process, commercial production has now started and the first batches of material have been delivered.

“Lutetium-177 is a highly demanded substance in many new cancer drugs. We are pleased to be able to offer this nuclide now in carrier-free form and thus of particularly high quality to our customers in the pharmaceutical industry. Due to the large number of studies in which lutetium-177 is being clinically tested worldwide, we expect an increasing demand for this isotope and related services in the coming years. With the new technology and production facilities in Europe, Asia and North America, we see ourselves as being excellently positioned to meet this demand,” explained Dr. Lutz Helmke, member of the Executive Board of Eckert & Ziegler AG.

Radiotherapeutic agents that are coupled with lutetium-177 prior to injection are currently under development for several types of cancer. Lutetium-177-based drugs for the treatment of metastatic prostate cancer are already in the clinical phase III trials. Therapeutic agents for other tumor types are also awaiting approval. In addition to its efficiency, the advantage of lutetium treatment is that it can be coupled with very precise diagnostics. The carrier substance of the therapeutic agent can be linked to a diagnostic radioisotope, for example gallium-68. Using special devices, so-called PET scanners, the response rate for the patient and thus the usefulness of treatment can be predicted with high precision in advance.

About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world’s largest providers of isotope-related components for radiation therapy and nuclear medicine, including GalliaPharm® for the production of gallium-68. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.

 

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.de

Contact

Get in touch

Contact us regarding your questions and we will get back to you as soon as possible.
By clicking send, you give your consent for processing your personal data in accordance with our Data Privacy Statement.
Permission required
In order to submit your request it is required to load a 3rd-party service (Google Re-Captcha spam protection system). You current privacy settings prevent this from happening automatically. By clicking the button below you explicitly allow to temporarily (on this page) load 3rd party services.